This report provides a comprehensive analysis of the global single-target MET tyrosine kinase inhibitors (TKIs) market, examining its trajectory from 2025 through 2032. The study evaluates key market drivers and trends across various product types, such as Capmatinib and Tepotinib, and applications including hospitals and retail pharmacies. By assessing regional dynamics in the Americas, APAC, and Europe, the report highlights growth opportunities and competitive strategies of leading players like Novartis and Merck within this specialized oncology segment.

Executive Overview

Market Definition

Single-target MET tyrosine kinase inhibitors (TKIs) are drugs specifically designed to block the activity of the MET receptor tyrosine kinase alone, focusing on disrupting the MET signaling pathway that promotes cancer cell growth, survival, and metastasis.

Global Market Outlook

The global Single-target MET TKIs market is projected to experience significant growth from 2025 through 2032, maintaining a steady compound annual growth rate throughout the forecast period.

Regional Market Insights

• United States: The market for Single-target MET TKIs in the United States is expected to expand steadily from 2025 to 2032.
• China: The Chinese market for Single-target MET TKIs is estimated to undergo consistent growth between 2025 and 2032.
• Europe: The European market for Single-target MET TKIs is projected to see a continuous increase in value from 2025 through 2032.

Report Scope and Methodology

Research Overview

LP Information, Inc. (LPI)'s newest research report, the “Single-target MET TKIs Industry Forecast,” reviews total world Single-target MET TKIs sales in 2025. The report provides a comprehensive analysis by region and market sector of projected Single-target MET TKIs sales for the period of 2026 through 2032. With Single-target MET TKIs sales broken down by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the world Single-target MET TKIs industry.

Analytical Depth

This Insight Report provides a comprehensive analysis of the global Single-target MET TKIs landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies with a focus on Single-target MET TKIs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Single-target MET TKIs market.

Methodology

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Single-target MET TKIs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Single-target MET TKIs market. The report presents a comprehensive overview, market shares, and growth opportunities of the Single-target MET TKIs market by product type, application, key manufacturers, and key regions and countries.

Market Segmentation

By Type

• Capmatinib
• Tepotinib
• Savolitinib
• Glumetinib
• Vebreltinib
• Other

By Application

• Hospital and Clinic
• Retail Pharmacies
• Other

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Market Players

The following companies have been profiled based on inputs gathered from primary experts and an analysis of the company's coverage, product portfolio, and market penetration:

• Novartis
• Merck
• WuXi STA
• Shanghai Hutchison Pharmaceuticals
• Haihe Biopharma
• CSPC Pharmaceutical
• Avistone Pharmaceuticals Biotechnology
• Asymchem

Market Concentration

Global key Single-target MET TKIs players include Novartis, Merck, WuXi STA, Shanghai Hutchison Pharmaceuticals, and Haihe Biopharma. In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

Key Questions Addressed

• What is the 10-year outlook for the global Single-target MET TKIs market?
• What factors are driving Single-target MET TKIs market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Single-target MET TKIs market opportunities vary by end market size?
• How does Single-target MET TKIs break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Single-target MET TKIs Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Single-target MET TKIs by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Single-target MET TKIs by Country/Region, 2021, 2025 & 2032

  • 2.2 Single-target MET TKIs Segment by Type

    • 2.2.1 Capmatinib

    • 2.2.2 Tepotinib

    • 2.2.3 Savolitinib

    • 2.2.4 Glumetinib

    • 2.2.5 Vebreltinib

    • 2.2.6 Other

    • 2.2.7 Single-target MET TKIs Sales by Type

      • 2.2.7.1 Global Single-target MET TKIs Sales Market Share by Type (2021-2026)
      • 2.2.7.2 Global Single-target MET TKIs Revenue and Market Share by Type (2021-2026)
      • 2.2.7.3 Global Single-target MET TKIs Sale Price by Type (2021-2026)

  • 2.3 Single-target MET TKIs Segment by Application

    • 2.3.1 Hospital and Clinic

    • 2.3.2 Retail Pharmacies

    • 2.3.3 Other

    • 2.3.4 Single-target MET TKIs Sales by Application

      • 2.3.4.1 Global Single-target MET TKIs Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Single-target MET TKIs Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Single-target MET TKIs Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Single-target MET TKIs Breakdown Data by Company

    • 3.1.1 Global Single-target MET TKIs Annual Sales by Company (2021-2026)

    • 3.1.2 Global Single-target MET TKIs Sales Market Share by Company (2021-2026)

  • 3.2 Global Single-target MET TKIs Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Single-target MET TKIs Revenue by Company (2021-2026)

    • 3.2.2 Global Single-target MET TKIs Revenue Market Share by Company (2021-2026)

  • 3.3 Global Single-target MET TKIs Sale Price by Company

  • 3.4 Key Manufacturers Single-target MET TKIs Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Single-target MET TKIs Product Location Distribution

    • 3.4.2 Players Single-target MET TKIs Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Single-target MET TKIs by Geographic Region

  • 4.1 World Historic Single-target MET TKIs Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Single-target MET TKIs Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Single-target MET TKIs Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Single-target MET TKIs Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Single-target MET TKIs Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Single-target MET TKIs Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Single-target MET TKIs Sales Growth

  • 4.4 APAC Single-target MET TKIs Sales Growth

  • 4.5 Europe Single-target MET TKIs Sales Growth

  • 4.6 Middle East & Africa Single-target MET TKIs Sales Growth

• 5 Americas

  • 5.1 Americas Single-target MET TKIs Sales by Country

    • 5.1.1 Americas Single-target MET TKIs Sales by Country (2021-2026)

    • 5.1.2 Americas Single-target MET TKIs Revenue by Country (2021-2026)

  • 5.2 Americas Single-target MET TKIs Sales by Type (2021-2026)

  • 5.3 Americas Single-target MET TKIs Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Single-target MET TKIs Sales by Region

    • 6.1.1 APAC Single-target MET TKIs Sales by Region (2021-2026)

    • 6.1.2 APAC Single-target MET TKIs Revenue by Region (2021-2026)

  • 6.2 APAC Single-target MET TKIs Sales by Type (2021-2026)

  • 6.3 APAC Single-target MET TKIs Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Single-target MET TKIs by Country

    • 7.1.1 Europe Single-target MET TKIs Sales by Country (2021-2026)

    • 7.1.2 Europe Single-target MET TKIs Revenue by Country (2021-2026)

  • 7.2 Europe Single-target MET TKIs Sales by Type (2021-2026)

  • 7.3 Europe Single-target MET TKIs Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Single-target MET TKIs by Country

    • 8.1.1 Middle East & Africa Single-target MET TKIs Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Single-target MET TKIs Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Single-target MET TKIs Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Single-target MET TKIs Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Single-target MET TKIs

  • 10.3 Manufacturing Process Analysis of Single-target MET TKIs

  • 10.4 Industry Chain Structure of Single-target MET TKIs

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Single-target MET TKIs Distributors

  • 11.3 Single-target MET TKIs Customer

• 12 World Forecast Review for Single-target MET TKIs by Geographic Region

  • 12.1 Global Single-target MET TKIs Market Size Forecast by Region

    • 12.1.1 Global Single-target MET TKIs Forecast by Region (2027-2032)

    • 12.1.2 Global Single-target MET TKIs Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Single-target MET TKIs Forecast by Type (2027-2032)

  • 12.7 Global Single-target MET TKIs Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Novartis

    • 13.1.1 Novartis Company Information

    • 13.1.2 Novartis Single-target MET TKIs Product Portfolios and Specifications

    • 13.1.3 Novartis Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Novartis Main Business Overview

    • 13.1.5 Novartis Latest Developments

  • 13.2 Merck

    • 13.2.1 Merck Company Information

    • 13.2.2 Merck Single-target MET TKIs Product Portfolios and Specifications

    • 13.2.3 Merck Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Merck Main Business Overview

    • 13.2.5 Merck Latest Developments

  • 13.3 WuXi STA

    • 13.3.1 WuXi STA Company Information

    • 13.3.2 WuXi STA Single-target MET TKIs Product Portfolios and Specifications

    • 13.3.3 WuXi STA Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 WuXi STA Main Business Overview

    • 13.3.5 WuXi STA Latest Developments

  • 13.4 Shanghai Hutchison Pharmaceuticals

    • 13.4.1 Shanghai Hutchison Pharmaceuticals Company Information

    • 13.4.2 Shanghai Hutchison Pharmaceuticals Single-target MET TKIs Product Portfolios and Specifications

    • 13.4.3 Shanghai Hutchison Pharmaceuticals Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Shanghai Hutchison Pharmaceuticals Main Business Overview

    • 13.4.5 Shanghai Hutchison Pharmaceuticals Latest Developments

  • 13.5 Haihe Biopharma

    • 13.5.1 Haihe Biopharma Company Information

    • 13.5.2 Haihe Biopharma Single-target MET TKIs Product Portfolios and Specifications

    • 13.5.3 Haihe Biopharma Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Haihe Biopharma Main Business Overview

    • 13.5.5 Haihe Biopharma Latest Developments

  • 13.6 CSPC Pharmaceutical

    • 13.6.1 CSPC Pharmaceutical Company Information

    • 13.6.2 CSPC Pharmaceutical Single-target MET TKIs Product Portfolios and Specifications

    • 13.6.3 CSPC Pharmaceutical Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 CSPC Pharmaceutical Main Business Overview

    • 13.6.5 CSPC Pharmaceutical Latest Developments

  • 13.7 Avistone Pharmaceuticals Biotechnology

    • 13.7.1 Avistone Pharmaceuticals Biotechnology Company Information

    • 13.7.2 Avistone Pharmaceuticals Biotechnology Single-target MET TKIs Product Portfolios and Specifications

    • 13.7.3 Avistone Pharmaceuticals Biotechnology Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Avistone Pharmaceuticals Biotechnology Main Business Overview

    • 13.7.5 Avistone Pharmaceuticals Biotechnology Latest Developments

  • 13.8 Asymchem

    • 13.8.1 Asymchem Company Information

    • 13.8.2 Asymchem Single-target MET TKIs Product Portfolios and Specifications

    • 13.8.3 Asymchem Single-target MET TKIs Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Asymchem Main Business Overview

    • 13.8.5 Asymchem Latest Developments

• 14 Research Findings and Conclusion